Related Experiment Video

Updated: May 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

c-MYC overexpression overrides TAK1 dependency in efficient tumorigenicity of AKT-transformed cells

Yulan Qu1, Li Zhang, Aihui Ma

  • 1Medical School of Fudan University, Shanghai, China.

Cancer Letters
|March 26, 2013
PubMed

Insights

Targeting Transforming growth factor activated kinase 1 (TAK1) inhibits AKT-transformed cancer cell growth by downregulating Mcl-1 and Bcl-2. Overexpressing c-Myc alleviates this effect, suggesting dual TAK1 and c-Myc targeting for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Transforming growth factor activated kinase 1 (TAK1) signaling promotes cell survival.
  • Emerging evidence suggests TAK1 as a therapeutic target in cancer treatment.
  • The role of TAK1 in AKT-transformed cells requires further elucidation.

Purpose of the Study:

  • To investigate the role of TAK1 in the tumorigenicity of AKT-transformed cells.
  • To determine the effect of TAK1 inhibition on apoptosis and key protein expression in AKT-transformed cells.
  • To explore the impact of c-Myc overexpression on TAK1 dependency in cancer cells.

Main Methods:

  • Utilized AKT-transformed and c-Myc-transformed cell models.
  • Administered TAK1 inhibitors to assess effects on anchorage-independent growth.
  • Analyzed apoptosis, Mcl-1, and Bcl-2 expression levels.
  • Evaluated tumorigenicity in vivo in c-Myc overexpressing cells.

Main Results:

  • TAK1 is essential for the tumorigenicity of AKT-transformed cells.
  • TAK1 inhibition induced apoptosis in AKT-transformed cells, linked to Mcl-1 and Bcl-2 downregulation.
  • TAK1 inhibition did not significantly affect c-Myc-transformed cell tumorigenicity.
  • Overexpression of c-Myc rendered AKT-transformed cells tolerant to TAK1 inhibition.

Conclusions:

  • TAK1 dependency in AKT-transformed cell tumorigenicity can be overcome by c-Myc.
  • Dual targeting of TAK1 and c-Myc presents a potential therapeutic strategy for specific cancers.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...